ID
ARRY

Integral Derivatives’s Array Biopharma Inc ARRY Stock Holding History

Integral Derivatives’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-30,000
Closed -$150K – 1681
2013
Q4 		$150K Buy
+30,000
New +$163K ﹤0.01% 1386

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Integral Derivatives's ARRY Position: Q2 2014 in Review

Integral Derivatives sold out of Array Biopharma Inc (ARRY) in Q2 2014, closing a stake of 21,612 shares — an estimated $89.4K sold.

Integral Derivatives first reported a position in ARRY in Q4 2013 and held it in 2 quarters. The position peaked at $104K in Q4 2013. 129 funds tracked by Wall St. Rank hold ARRY as of Q2 2014.

  • Integral Derivatives reported no remaining Array Biopharma Inc position as of Q2 2014 after selling out during the quarter.
  • Integral Derivatives sold 21,612 Array Biopharma Inc shares in Q2 2014, an estimated $89.4K.
  • Integral Derivatives first reported a position in Array Biopharma Inc in Q4 2013 and held it in 2 quarters.
  • Integral Derivatives's Array Biopharma Inc position peaked at $104K in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2014.

Based on Integral Derivatives's 13F filing for Q2 2014, filed 7 Aug 2014.